Sterling Capital Management’s Lam Research LRCX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$17.7M Sell
82,965
-6,158
-7% -$1.38M 0.34% 62
2025
Q4
$15.3M Buy
89,123
+13,197
+17% +$2.05M 0.25% 78
2025
Q3
$10.2M Buy
75,926
+8,245
+12% +$873K 0.15% 93
2025
Q2
$6.59M Buy
67,681
+16,664
+33% +$1.32M 0.09% 145
2025
Q1
$3.71M Sell
51,017
-44,787
-47% -$3.53M 0.06% 227
2024
Q4
$6.92M Buy
+95,804
New +$7.27M 0.09% 141
2019
Q3
$10.8M Sell
467,510
-189,600
-29% -$3.98M 0.1% 177
2019
Q2
$12.3M Buy
657,110
+410,450
+166% +$7.79M 0.12% 163
2019
Q1
$4.42M Sell
246,660
-86,550
-26% -$1.44M 0.04% 257
2018
Q4
$4.54M Buy
333,210
+93,080
+39% +$1.33M 0.05% 240
2018
Q3
$3.64M Sell
240,130
-421,180
-64% -$7.19M 0.03% 294
2018
Q2
$11.4M Buy
661,310
+175,560
+36% +$3.38M 0.11% 180
2018
Q1
$9.87M Buy
485,750
+400,500
+470% +$7.93M 0.09% 193
2017
Q4
$1.57M Buy
85,250
+1,000
+1% +$19.6K 0.01% 468
2017
Q3
$1.56M Buy
+84,250
New +$1.37M 0.01% 472

Other funds holding LRCX

Sterling Capital Management's LRCX Position: Q1 2026 in Review

Sterling Capital Management reduced its Lam Research (LRCX) stake by 6.9% in Q1 2026, selling an estimated $1.38M and leaving 82,965 shares worth $17.7M. The position accounts for 0.34% of the portfolio, ranked #62.

Sterling Capital Management first reported a position in LRCX in Q3 2017 and has held it in 15 quarters since. 2,630 funds tracked by Wall St. Rank hold LRCX as of Q1 2026.

  • Sterling Capital Management held 82,965 shares of Lam Research worth $17.7M as of Q1 2026.
  • Sterling Capital Management sold 6,158 Lam Research shares in Q1 2026, an estimated $1.38M.
  • Lam Research made up 0.34% of Sterling Capital Management's portfolio in Q1 2026, its #62 holding.
  • Sterling Capital Management first reported a position in Lam Research in Q3 2017 and has held it in 15 quarters since.
  • 2,630 funds tracked by Wall St. Rank held Lam Research as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.